|
A more recent version of this article appeared on August 4, 2006
Papers In Press, published online ahead of print June 2, 2006
J. Biol. Chem, 10.1074/jbc.M602909200
Submitted on March 28, 2006
Revised on May 30, 2006
Accepted on June 2, 2006
Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer's disease amyloid neuropathology by calorie restriction
Weiping Qin, Tianle Yang, Lap Ho, Zhong Zhao, Jun Wang, Linghong Chen, Meenakshisundaram Thiyagarajan, Donal MacGrogan, Joseph T. Rodgers, Pere Puigserver, Junichi Sadoshima, Haiteng Deng H., Steven Pedrini, Samuel Gandy, Anthony Sauve, and Giulio M. Pasinetti
Psychiatry, Mount Sinai School of Medicine, New York, NY 10029
Corresponding Author: giulio.pasinetti{at}mssm.edu
Nicotinamide adenine dinucleotide (NAD)+r-dependent sirtuins have been identified to be key regulators in the lifespan extending effects of calorie restriction (CR) in a number of species. In this study we report for the first time that promotion of the NAD+r-dependent sirtuin, SIRT1 mediated deacetylase activity, may be a mechanism by which CR influences Alzheimers disease (AD)-type amyloid neuropathology. Most importantly, we report that the predicted attenuation of -amyloid (A ) content in the brain during CR can be reproduced in mouse neurons in vitro by manipulating cellular SIRT1 expression/activity through mechanisms involving the regulation of the serine/threonine Rho kinase ROCK1, known in part, for its role in the inhibition of the non-amyloidogenic -secretase processing of the amyloid precursor protein (APP). Conversely, we found that the expression of constitutively active ROCK1 in vitro cultures significantly prevented SIRT1 mediated response, suggesting that -secretase activity is required for SIRT1 mediated prevention of AD-type amyloid neuropathology. Consistently we found that the expression of exogenous human (h)SIRT1 in the brain of hSIRT1 transgenics also resulted in decreased ROCK1 expression and elevated -secretase activity in vivo. These results demonstrate for the first time a role for SIRT1 activation in the brain as a novel mechanism through which CR may influence AD amyloid neuropathology. The study provides a potentially novel pharmacological strategy for AD prevention and/or treatment.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. O. Bauer, H. K. Wong, F. Oyama, A. Goswami, M. Okuno, Y. Kino, H. Miyazaki, and N. Nukina
Inhibition of Rho Kinases Enhances the Degradation of Mutant Huntingtin
J. Biol. Chem.,
May 8, 2009;
284(19):
13153 - 13164.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Qin, V. Haroutunian, P. Katsel, C. P. Cardozo, L. Ho, J. D. Buxbaum, and G. M. Pasinetti
PGC-1{alpha} Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia
Arch Neurol,
March 1, 2009;
66(3):
352 - 361.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Ramadori, C. E. Lee, A. L. Bookout, S. Lee, K. W. Williams, J. Anderson, J. K. Elmquist, and R. Coppari
Brain SIRT1: Anatomical Distribution and Regulation by Energy Availability
J. Neurosci.,
October 1, 2008;
28(40):
9989 - 9996.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Catoire, M. Y. Pasco, A. Abu-Baker, S. Holbert, C. Tourette, B. Brais, G. A. Rouleau, J. A. Parker, and C. Neri
Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1
Hum. Mol. Genet.,
July 15, 2008;
17(14):
2108 - 2117.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. T. Pfluger, D. Herranz, S. Velasco-Miguel, M. Serrano, and M. H. Tschop
Sirt1 protects against high-fat diet-induced metabolic damage
PNAS,
July 15, 2008;
105(28):
9793 - 9798.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Sauve
NAD+ and Vitamin B3: From Metabolism to Therapies
J. Pharmacol. Exp. Ther.,
March 1, 2008;
324(3):
883 - 893.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kuningas, M. Putters, R. G. J. Westendorp, P. E. Slagboom, and D. van Heemst
SIRT1 Gene, Age-Related Diseases, and Mortality: The Leiden 85-Plus Study
J. Gerontol. A Biol. Sci. Med. Sci.,
September 1, 2007;
62(9):
960 - 965.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Yamamoto, K. Schoonjans, and J. Auwerx
Sirtuin Functions in Health and Disease
Mol. Endocrinol.,
August 1, 2007;
21(8):
1745 - 1755.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A Varady and M. K Hellerstein
Alternate-day fasting and chronic disease prevention: a review of human and animal trials
Am. J. Clinical Nutrition,
July 1, 2007;
86(1):
7 - 13.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Guarente
Sirtuins in Aging and Disease
Cold Spring Harb Symp Quant Biol,
January 1, 2007;
72(0):
483 - 488.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Thomas and M. Fenech
A review of genome mutation and Alzheimer's disease
Mutagenesis,
January 1, 2007;
22(1):
15 - 33.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. D. Roberson and L. Mucke
100 Years and Counting: Prospects for Defeating Alzheimer's Disease
Science,
November 3, 2006;
314(5800):
781 - 784.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Papers of Note
Sci. Aging Knowl. Environ.,
June 28, 2006;
2006(10):
nw10 - nw10.
[Full Text]
|
 |
|
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|